Insight

Leila Tchelebi: Officially in print. Our QA Analysis of Alliance A021501

Photo from Leila Tchelebi/X

Aug 17, 2024, 07:54

Leila Tchelebi: Officially in print. Our QA Analysis of Alliance A021501

Leila Tchelebi, Associate Professor of Radiation Medicine at Zucker School of Medicine, shared a post on X, about a recent paper published in Science Direct.

“Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas”

Authors: Leila Tchelebi et al.

“Officially in print! Our QA Analysis of Alliance A021501, the 1st RCT of neoadjuvant SBRT for Pancreatic Cancer.”

Source: Leila Tchelebi/X

Adenocarcinoma Alliance A021501 Alliance for Clinical Trials in Oncology ASTRO cancer Joseph Michael Herman Leila Tchelebi Michael Chuong OncoDaily Oncology Pancreatic Cancer radiation therapy SBRT Science Direct Zucker School of Medicine

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage